drugset / Trial / NCT06701539

Liposomal Bupivacaine for Postoperative Pain After Craniotomy

NCT06701539 ↗

Not yet recruiting 106 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Acute postoperative pain is a common postoperative adverse reaction. It refers to acute pain that occurs immediately after surgery and usually lasts no longer than 3-7. Among the craniotomy approaches, patients undergoing supratentorial craniotomy with temporal approach had a higher incidence of moderate to severe pain within 24 hours. In the management of postoperative acute pain, multimodal analgesia is recommended. Liposomal bupivacaine was encapsulated by liposomal vesicles and released slowly, lasting up to 72 hours. The long action time also makes the time window of postoperative acute pain completely covered, thus helping patients better control pain. At present, there is an obvious lack of clinical studies on the effectiveness and specific duration of liposome bupivacaine for postoperative acute pain, especially in neurosurgical craniotomy population with transtemporal incision approach, which is a high-risk group for postoperative pain in neurosurgery.

Timeline

Start
2024-12-01
Primary completion
2025-06-01
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Liposome bupivacaine Unknown — Other
Comparator Ropivacaine Other / unclassified 0.5 % Other

Indications

No indication recorded.